Press Releases

• $126.3 Million In Total Gross Proceeds from Warrant Distribution.
• Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.
• Over 735 Patients Have Completed a Phase 3 Trial of Simufilam.

AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million... (continue reading...)

• Engineering of X-Editors (XE), Scribe’s proprietary genome editing platform, for potency and specificity enables XE to become the first non-Cas9-based molecule to achieve saturating levels of editing in the NHP liver (exceeding 75% whole liver editing) without any detectable off-targets
• Data also highlight the ability of XE to achieve safe and saturated levels of editing in transduced photoreceptors in the mouse retina and rescue of visual response in a mouse... (continue reading...)

• $126.3 Million In Total Gross Proceeds from Warrant Distribution.
• Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam.
• Over 735 Patients Have Completed a Phase 3 Trial of Simufilam.

AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million... (continue reading...)

Vancouver, British Columbia--(Newsfile Corp. - May 10, 2024) - BMEX Gold Inc. (TSXV: BMEX) (FSE: 8M0) ("BMEX" or the "Company") announces that it is undertaking a non-brokered private placement financing of for aggregate gross proceeds of up to $1,250,000 (the "Offering").

The Offering will consist of the sale of up to 6,666,667 flow-through units ("FT Unit") at $0.15 for gross proceeds of up to $1,000,000 and 1,666,667 non-flow-through units ("NFT Units") at $0.15 for... (continue reading...)

TORONTO, May 10, 2024 /PRNewswire/ - Sun Life Financial Inc. (the "Company") (TSX: SLF) (NYSE: SLF) announced that the 11 nominees listed in the management information circular dated March 15, 2024 were elected as directors of the Company. The detailed results of the vote held yesterday at its annual meeting of common shareholders are set out below.

Nominee

Votes For

% For

Votes Withheld

% Withheld

Deepak Chopra

312,237,106

99.3 %

2,179,278

0.7 %

Stephanie L.... (continue reading...)